Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008: Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78. Free full-text

Ovarian Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 74 articles: HTML format

Single Articles

June 2008
1. O'BRIEN PM , Davies MJ, Scurry JP, Smith AN, et al
   The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
   Br J Cancer. 2008;98:1880.
   PubMed     Related articles   
   
   
   
2. LEUNG EL , Fraser M, Fiscus RR, Tsang BK, et al
   Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance.
   Br J Cancer. 2008;98:1803-9.
   PubMed     Related articles    Abstract available
   
   
   
3. WERNLI KJ , Newcomb PA, Hampton JM, Trentham-Dietz A, et al
   Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity.
   Br J Cancer. 2008;98:1781-3.
   PubMed     Related articles    Abstract available
   
   
   
4. VASEY PA , Gore M, Wilson R, Rustin G, et al
   A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
   Br J Cancer. 2008;98:1774-80.
   PubMed     Related articles    Abstract available
   
   
   May 2008
5. FERRANDINA G , Petrillo M, Carbone A, Zannoni G, et al
   Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
6. CALCAGNO AM , Fostel JM, To KK, Salcido CD, et al
   Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
   Br J Cancer. 2008;98:1515-24.
   PubMed     Related articles    Abstract available   Free Full Text
   
   
   April 2008
7. LIM SL , Smith P, Syed N, Coens C, et al
   Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
   Br J Cancer. 2008;98:1452-6.
   PubMed     Related articles    Abstract available
   
   
   March 2008
8. O'BRIEN PM , Davies MJ, Scurry JP, Smith AN, et al
   The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
   Br J Cancer. 2008;98:1085-93.
   PubMed     Related articles    Abstract available
   
   
   
9. WRIGHT JD , Doan T, McBride R, Jacobson JS, et al
   Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
10. CHAN JK , Fuh K, Shin JY, Cheung MK, et al
    The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?
    Br J Cancer. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
11. ANTONIOU AC , Cunningham AP, Peto J, Evans DG, et al
    The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
    Br J Cancer. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
12. AHMED N , Riley C, Quinn MA
    An immunohistochemical perspective of PPARbeta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours.
    Br J Cancer. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
13. GOTO T , Takano M, Hirata J, Tsuda H, et al
    The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.
    Br J Cancer. 2008;.
    PubMed     Related articles    Abstract available
    
    
    February 2008
14. YANG X , Fraser M, Abedini MR, Bai T, et al
    Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt.
    Br J Cancer. 2008;98:803-8.
    PubMed     Related articles    Abstract available
    
    
    
15. FRUSCIO R , Colombo N, Lissoni AA, Garbi A, et al
    A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
    Br J Cancer. 2008;.
    PubMed     Related articles    Abstract available
    
    
    January 2008
16. PEARCE CL , Wu AH, Gayther SA, Bale AE, et al
    Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis.
    Br J Cancer. 2008;98:282-288.
    PubMed     Related articles    Abstract available
    
    
    
17. ALAM SM , Fujimoto J, Jahan I, Sato E, et al
    Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
    Br J Cancer. 2008;.
    PubMed     Related articles    Abstract available
    
    
    December 2007
18. GRANSTROM C , Sundquist J, Hemminki K
    Population attributable fractions for ovarian cancer in Swedish women by morphological type.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    November 2007
19. BLECHSCHMIDT K , Sassen S, Schmalfeldt B, Schuster T, et al
    The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
20. KRASNER CN , McMeekin DS, Chan S, Braly PS, et al
    A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    October 2007
21. GAKIOPOULOU H , Korkolopoulou P, Levidou G, Thymara I, et al
    Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications.
    Br J Cancer. 2007;97:1124-34.
    PubMed     Related articles    Abstract available
    
    
    
22. STEEVENS J , Schouten LJ, Verhage BA, Goldbohm RA, et al
    Tea and coffee drinking and ovarian cancer risk: results from the Netherlands Cohort Study and a meta-analysis.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
23. RAY-COQUARD I , Paraiso D, Guastalla JP, Leduc B, et al
    Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    September 2007
24. SATOH T , Oki A, Uno K, Sakurai M, et al
    High incidence of silent venous thromboembolism before treatment in ovarian cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
25. WYNNE P , Newton C, Ledermann JA, Olaitan A, et al
    Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    July 2007
26. MINAS V , Rolaki A, Kalantaridou SN, Sidiropoulos J, et al
    Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
27. CHAN JK , Kapp DS, Cheung MK, Osann K, et al
    The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
28. SODEK KL , Ringuette MJ, Brown TJ
    MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    June 2007
29. WILD SH , Bryden JR, Lee RJ, Bishop JL, et al
    Cancer, cardiovascular disease and diabetes mortality among women with a history of endometrial cancer.
    Br J Cancer. 2007;96:1747-9.
    PubMed     Related articles    Abstract available
    
    
    May 2007
30. CHAN JK , Urban R, Hu JM, Shin JY, et al
    The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
31. YU J , Roy D, Brockmeyer AD, Dubeau L, et al
    Increased chromosomal stability in cultures of ovarian tumours of low malignant potential compared to cystadenomas.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
32. TOMLINSON VA , Newbery HJ, Bergmann JH, Boyd J, et al
    Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus.
    Br J Cancer. 2007;96:1613-20.
    PubMed     Related articles    Abstract available
    
    
    
33. PIGNATA S , Scambia G, Pisano C, Breda E, et al
    A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gy
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
34. CHAN JK , Urban R, Cheung MK, Osann K, et al
    Ovarian cancer in younger vs older women: a population-based analysis.
    Br J Cancer. 2007;96:1492.
    PubMed     Related articles   
    
    
    
35. HERMSEN BB , Olivier RI, Verheijen RH, van Beurden M, et al
    No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
    Br J Cancer. 2007;96:1335-42.
    PubMed     Related articles    Abstract available
    
    
    April 2007
36. LASSUS H , Butzow R
    The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles   
    
    
    
37. DE GRAEFF P , Hall J, Crijns AP, de Bock GH, et al
    Reply: The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles   
    
    
    
38. BACKEN AC , Cole CL, Lau SC, Clamp AR, et al
    Heparan sulphate synthetic and editing enzymes in ovarian cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    March 2007
39. ALBREKTSEN G , Heuch I, Thoresen S, Kvale G, et al
    Twin births, sex of children and maternal risk of ovarian cancer: a cohort study in Norway.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
40. KUMAR SR , Masood R, Spannuth WA, Singh J, et al
    The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
41. FOSTER C , Watson M, Eeles R, Eccles D, et al
    Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.
    Br J Cancer. 2007;96:718-24.
    PubMed     Related articles    Abstract available
    
    
    February 2007
42. CHAN JK , Urban R, Cheung MK, Osann K, et al
    Ovarian cancer in younger vs older women: a population-based analysis.
    Br J Cancer. 2007;96:534.
    PubMed     Related articles   
    
    
    
43. SWERDLOW AJ , Jones ME
    Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case-control study.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    January 2007
44. SHAN SJ , Scorilas A, Katsaros D, Diamandis EP, et al
    Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.
    Br J Cancer. 2007;96:362-72.
    PubMed     Related articles    Abstract available
    
    
    
45. KOMMOSS S , du Bois A, Ridder R, Trunk MJ, et al
    Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gy
    Br J Cancer. 2007;96:306-13.
    PubMed     Related articles    Abstract available
    
    
    
46. PILS D , Pinter A, Reibenwein J, Alfanz A, et al
    In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
47. LEVY-LAHAD E , Friedman E
    Cancer risks among BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2007;96:11-5.
    PubMed     Related articles    Abstract available
    
    
    
48. GRUNEWALD TG , Kammerer U, Winkler C, Schindler D, et al
    Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
49. UNO K , Homma S, Satoh T, Nakanishi K, et al
    Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
50. HOSONO S , Kajiyama H, Terauchi M, Shibata K, et al
    Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    December 2006
51. DANFORTH KN , Tworoger SS, Hecht JL, Rosner BA, et al
    A prospective study of postmenopausal hormone use and ovarian cancer risk.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    November 2006
52. INO K , Yoshida N, Kajiyama H, Shibata K, et al
    Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
53. BODO J , Hunakova L, Kvasnicka P, Jakubikova J, et al
    Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations.
    Br J Cancer. 2006;95:1348-53.
    PubMed     Related articles    Abstract available
    
    
    October 2006
54. CHAN JK , Urban R, Cheung MK, Osann K, et al
    Ovarian cancer in younger vs older women: a population-based analysis.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
55. WANG Y , Liu VW, Xue WC, Cheung AN, et al
    Association of decreased mitochondrial DNA content with ovarian cancer progression.
    Br J Cancer. 2006;95:1087-91.
    PubMed     Related articles    Abstract available
    
    
    
56. MOURITS MJ , van der Velde NM, Arts HJ, de Bock GH, et al
    High percentage of abnormal findings on TVU needs further discussion.
    Br J Cancer. 2006;95:1125.
    PubMed     Related articles   
    
    
    
57. JACOBS IJ , Mackay J, Menon U, Skates SJ, et al
    Familial ovarian screening - effective or ineffective?
    Br J Cancer. 2006;95:1124.
    PubMed     Related articles   
    
    
    September 2006
58. BODMER D , Ligtenberg MJ, van der Hout AH, Gloudemans S, et al
    Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
    Br J Cancer. 2006;95:757-62.
    PubMed     Related articles    Abstract available
    
    
    
59. BIADE S , Marinucci M, Schick J, Roberts D, et al
    Gene expression profiling of human ovarian tumours.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    August 2006
60. MAGGIONI A , Benedetti Panici P, Dell'anna T, Landoni F, et al
    Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
61. DE GRAEFF P , Hall J, Crijns AP, de Bock GH, et al
    Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    July 2006
62. GOEDERT JJ , Schairer C, McNeel TS, Hessol NA, et al
    Risk of breast, ovary, and uterine corpus cancers among 85 268 women with AIDS.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
63. MAGGI R , Lissoni A, Spina F, Melpignano M, et al
    Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
64. CUMMINGS J , Ranson M, Lacasse E, Ganganagari JR, et al
    Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
    Br J Cancer. 2006;95:42-8.
    PubMed     Related articles    Abstract available
    
    
    May 2006
65. SUNDAR SS , Zhang H, Brown P, Manek S, et al
    Role of lymphangiogenesis in epithelial ovarian cancer.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
66. YOKOYAMA Y , Moriya T, Takano T, Shoji T, et al
    Clinical outcome and risk factors for recurrence in borderline ovarian tumours.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
67. DE JONGE ME , Huitema AD, Beijnen JH, Rodenhuis S, et al
    High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
    Br J Cancer. 2006;94:1226-30.
    PubMed     Related articles    Abstract available
    
    
    April 2006
68. BAEK JH , Kim JG, Jeon SB, Chae YS, et al
    Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
69. TAKANO M , Kikuchi Y, Yaegashi N, Kuzuya K, et al
    Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
70. PARK SR , Chun JH, Yu MS, Lee JH, et al
    Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    March 2006
71. WILKINSON PM , Antonopoulos M, Lahousen M, Lind M, et al
    Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    February 2006
72. HAMILTON CA , Cheung MK, Osann K, Chen L, et al
    Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
73. KOHNO Y , Matsuki Y, Tanimoto A, Izumi H, et al
    Expression of Y-box-binding protein dbpC/contrin, a potentially new cancer/testis antigen.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
74. WANG Y , Hewitt SM, Liu S, Zhou X, et al
    Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: